Showing 1 - 9 results of 9 for search 'Hongming Pan', query time: 0.02s Refine Results
  1. 1
    De Novo MET-amplified NSCLC treated with savolitinib achieved remarkable tumor regression: a case report and review of literature

    De Novo MET-amplified NSCLC treated with savolitinib achieved remarkable tumor regression: a case report and review of literature by Jin Sheng, Juan Jiao, Na Yan, Hongming Pan

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    SMARCA4-deficient NSCLC treated with first-line tislelizumab and fruquintinib achieved remarkable tumor regression: case report and literature review

    SMARCA4-deficient NSCLC treated with first-line tislelizumab and fruquintinib achieved remarkable tumor regression: case report and literature review by Jie Dong, Jinli Zhang, Hongming Pan, Chongwei Wang, Jin Sheng

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Correlation between p-STAT3 overexpression and prognosis in lung cancer: A systematic review and meta-analysis.

    Correlation between p-STAT3 overexpression and prognosis in lung cancer: A systematic review and meta-analysis. by Mengting Tong, Jing Wang, Nanyu Jiang, Hongming Pan, Da Li

    Published 2017-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    The prealbumin-CD19+ index predicts surgical survival in patients with GC

    The prealbumin-CD19+ index predicts surgical survival in patients with GC by Hongming Pan, Hao Sun, Yanjiao Zuo, Ruihu Zhao, Yingwei Xue, Hongjiang Song

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Analysis of potential genes and pathways associated with the colorectal normal mucosa–adenoma–carcinoma sequence

    Analysis of potential genes and pathways associated with the colorectal normal mucosa–adenoma–carcinoma sequence by Zhuoxuan Wu, Zhen Liu, Weiting Ge, Jiawei Shou, Liangkun You, Hongming Pan, Weidong Han

    Published 2018-06-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2–positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trialResearch in context

    Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2–positive locally advanced/metastatic gastric or gastroesophageal junc... by Zhi Peng, Ping Chen, Jin Lu, Yiye Wan, Yulong Zheng, Feng Ye, Jianwei Yang, Ying Liu, Hongming Pan, Meili Sun, Qingxia Fan, Ying Yuan, Kai Chen, Zhuoer Sun, Han Tian, Ye Xia, Lin Shen

    Published 2025-09-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

    Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study by Lin Shen, Qing Zhou, Ting Sun, Jie Wang, Hongming Pan, Yi-Long Wu, Jun Zhao, Jun Guo, Qingyuan Zhang, Ying Yuan, Yuxian Bai, Tianshu Liu, Yongqian Shu, Siyang Wang, Aiping Zhou, Dingwei Ye, Yujuan Gao, Silu Yang, Zuobai Wang

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification

    Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification by Jiajia Yuan, Lin Shen, Tian Shu Liu, HuiTing Xu, Jianwei Yang, Jia Wei, Haiping Jiang, Yanhong Deng, Hongming Pan, Yusheng Wang, Xiaotian Zhang, Zhi Peng, Changsong Qi, Lingli Zhang, Peiwen Hsu, Lin Song, Lei Mu, Qiao Sun, Jifang Gong, Cheng Lyu

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation

    Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation by Dan-Yun Ruan, Hao-Xiang Wu, Ye Xu, Pamela N. Munster, Yanhong Deng, Gary Richardson, Dong Yan, Myung-Ah Lee, Keun-Wook Lee, Hongming Pan, Steven Hager, Xingya Li, Shaozhong Wei, Xinfang Hou, Craig Underhill, Michael Millward, Ina Nordman, Jingdong Zhang, Jianzhen Shan, Guohong Han, Jaspreet Grewal, Shirish M. Gadgeel, Rachel E. Sanborn, Seok Jae Huh, Xiaohua Hu, Yihong Zhang, Ziyong Xiang, Laisheng Luo, Xiaoxi Xie, Zhe Shi, Yaolin Wang, Ling Zhang, Feng Wang, Rui-Hua Xu

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: